News and updates
Help disseminate IVDR Questionnaire - Share with diagnostic laboratories in your…
The new EU Regulation on in vitro diagnostic medical devices (IVDR) will come into full effect per May 26, 2022 and will have substantial consequences for diagnostic laboratories.
VIRTUAL: EHA-TSH Hematology Tutorial
June 25&26, 2021 Meeting Chairs: Prof S Eichinger (European Hematology Association) Prof H Özsan (Turkish Society of Hematology) In close collaboration with the Turkish Society of Hematology, EHA has annually organized live, joint tutorials…
Congratulations to the 2021 Research Grant winners!
The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.
EHA-SWG on AAA a virtual meeting with a worldwide approach covering all aspects …
Live days: April 29-30, 2021 Content available: April 22, 2021 – May 29, 2021 Chair: Prof Dr C Dufour Junior and senior hematologists from all over the world gathered on April 29-30, 2021…
Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices:…
Urgent actions are needed now to prevent a collapse of diagnostic testing.
Message from the EHA Board
After more than a decade of tireless work to further EHA’s mission our Executive Director, Carin Smand, has unfortunately announced that she will be leaving our organization.
The EHA Guidelines Workshop, a meaningful and successful first Series!
November 2020 – April 2021 In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.
Helping steer EHA into the future
In 2020, EHA launched the Taskforce on Diversity, Equity, and Inclusion with an EHA Board mandate.
GoCART Coalition - Call for research proposals within Work Package 6: Scientific…
Dear GoCART community, With more than 1500 CAR-T infusions registered in the EBMT registry, EHA and EBMT are proud to announce a series of scientific calls within Work Package 6: Scientific…
Virtual: EHA-PTHiT Hematology Mini Tutorial - a report
VIRTUAL: EHA-PTHiT Hematology Mini Tutorial April 12 -13, 2021 Meeting Chairs: Prof G Gaidano (European Hematology Association) Prof I Hus (Polish Society of Hematology and Transfusion) Prof T Robak (Polish Society of Hematology and Transfusion) As…
15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conferenc…
October 26-31, 2020 | Virtual Global Conference Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty, R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell In the last…
15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conferenc…
October 26-31, 2020 | Virtual Global Conference Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty, R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell In the last…
EHA-EBMT 3rd European CAR T-cell Meeting (Virtual)
Dates: February 4-6, 2021 Chairs: H Einsele (EHA) & C Chabannon (EBMT) For the 3rd time now the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT)…
Celebrating the International Day of Women & Girls in Science
"We (women) need to empower ourselves, learn to be confident and understand that are many ways of being a successful researcher and leader. But to make this possible we need institutions and research associations to help us by providing secure networks, structures and resources that help in boosting this change.” - Dr Alba Maiques-Diaz (Spain).
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immun…
T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.